Thomas L Emmons
Overview
Explore the profile of Thomas L Emmons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Emmons T, Wrightstone A, Baima E, Brown S, Sommers C, Hirsch J, et al.
Protein Pept Lett
. 2012 Apr;
19(5):485-91.
PMID: 22486643
The Janus kinase (JAK) family consists of four members: JAK-1, -2, -3 and tyrosine kinase 2 (TYK-2). Recent work suggests that cytokine signaling through TYK-2 may play a critical role...
2.
Chrencik J, Patny A, Leung I, Korniski B, Emmons T, Hall T, et al.
J Mol Biol
. 2010 May;
400(3):413-33.
PMID: 20478313
Janus kinases (JAKs) are critical regulators of cytokine pathways and attractive targets of therapeutic value in both inflammatory and myeloproliferative diseases. Although the crystal structures of active JAK1 and JAK2...
3.
Korniski B, Wittwer A, Emmons T, Hall T, Brown S, Wrightstone A, et al.
Biochem Biophys Res Commun
. 2010 May;
396(2):543-8.
PMID: 20435017
The Janus kinase family consists of four members: JAK-1, -2, -3 and TYK-2. While JAK-2 and JAK-3 have been well characterized biochemically, there is little data on TYK-2. Recent work...
4.
Hall T, Emmons T, Chrencik J, Gormley J, Weinberg R, Leone J, et al.
Protein Expr Purif
. 2009 Sep;
69(1):54-63.
PMID: 19781647
Janus-associated kinases (JAKs) play critical roles in cytokine signaling, and have emerged as viable therapeutic targets in inflammation and oncology related diseases. To date, targeting JAK proteins with highly selective...
5.
Emmons T, Mathis K, Shuck M, Reitz B, Curran D, Walker M, et al.
Protein Expr Purif
. 2009 Feb;
65(2):133-9.
PMID: 19189860
Soluble guanylate cyclase (sGC) has been purified from 100 L cell culture infected by baculovirus using the newer and highly effective titerless infected-cells preservation and scale-up (TIPS) method. Successive passage...
6.
Wasilko D, Lee S, Stutzman-Engwall K, Reitz B, Emmons T, Mathis K, et al.
Protein Expr Purif
. 2009 Jan;
65(2):122-32.
PMID: 19174191
Compounds capable of stimulating soluble guanylate cyclase (sGC) activity might become important new tools to treat hypertension. While rational design of these drugs would be aided by elucidation of the...
7.
Mathis K, Emmons T, Curran D, Day J, Tomasselli A
Protein Expr Purif
. 2008 Apr;
60(1):58-63.
PMID: 18430586
Soluble guanylate cyclase (sGC), the main target of nitric oxide (NO), is a cytosolic, heme-containing, heterodimeric enzyme that catalyzes the conversion of guanosine 5'-triphosphate (GTP) to 3,5'-cyclic guanosine monophosphate (cGMP)...
8.
Kortum S, Benson T, Bienkowski M, Emmons T, Prince D, Paddock D, et al.
Bioorg Med Chem Lett
. 2007 Apr;
17(12):3378-83.
PMID: 17434734
The design and synthesis of a novel series of potent BACE1 hydroxyethylamine inhibitors. These inhibitors feature hydrogen bonding substituents at the C-5 position of the isophthalamide ring with improved selectivity...
9.
Maillard M, Hom R, Benson T, Moon J, Mamo S, Bienkowski M, et al.
J Med Chem
. 2007 Feb;
50(4):776-81.
PMID: 17300163
The design and synthesis of a novel series of potent and cell permeable peptidomimetic inhibitors of the human beta-secretase (BACE) are described. These inhibitors feature a hydroxyethyl secondary amine isostere...
10.
Freskos J, Fobian Y, Benson T, Moon J, Bienkowski M, Brown D, et al.
Bioorg Med Chem Lett
. 2006 Oct;
17(1):78-81.
PMID: 17049233
We describe an optimized series of acyclic hydroxyethylamine transition state isosteres of beta-secretase that incorporates a variety of P(2) side chains that yield potent inhibitors with excellent cellular activity. A...